These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35355299)

  • 1. Extensive cutaneous leukocytoclastic vasculitis after Sinopharm vaccine: Case report and review of the literature.
    Azzazi Y; Abdelkader HA; Khedr H; El-Komy MHM
    J Cutan Pathol; 2022 Aug; 49(8):736-742. PubMed ID: 35355299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Onset of leukocytoclastic vasculitis following covid-19 vaccination: case based comprehensive review.
    Miskovic R; Radovic S; Arandjelovic S; Plavsic A; Reljic V; Peric J; Brkovic V; Stojanovic M
    Rheumatol Int; 2024 Nov; 44(11):2621-2635. PubMed ID: 39284920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans.
    Vályi-Nagy I; Matula Z; Gönczi M; Tasnády S; Bekő G; Réti M; Ajzner É; Uher F
    Geroscience; 2021 Oct; 43(5):2321-2331. PubMed ID: 34633612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous small-vessel vasculitis following COVID-19 vaccine.
    Kar BR; Singh BS; Mohapatra L; Agrawal I
    J Cosmet Dermatol; 2021 Nov; 20(11):3382-3383. PubMed ID: 34529877
    [No Abstract]   [Full Text] [Related]  

  • 5. Leukocytoclastic vasculitis flare following the COVID-19 vaccine.
    Cohen SR; Prussick L; Kahn JS; Gao DX; Radfar A; Rosmarin D
    Int J Dermatol; 2021 Aug; 60(8):1032-1033. PubMed ID: 33928638
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety and efficacy of Sinopharm vaccine (BBIBP-CorV) in elderly population of Faisalabad district of Pakistan.
    Nadeem I; Ul Munamm SA; Ur Rasool M; Fatimah M; Abu Bakar M; Rana ZK; Khatana UF; Jordon L; Saqlain M; Mahdi N; McLoughlin H
    Postgrad Med J; 2023 Jun; 99(1171):463-469. PubMed ID: 37294716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukocytoclastic vasculitis after COVID-19 vaccination.
    Altun E; Kuzucular E
    Dermatol Ther; 2022 Mar; 35(3):e15279. PubMed ID: 34931412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leukocytoclastic vasculitis after exposure to COVID-19 vaccine.
    Fritzen M; Funchal GDG; Luiz MO; Durigon GS
    An Bras Dermatol; 2022; 97(1):118-121. PubMed ID: 34836739
    [No Abstract]   [Full Text] [Related]  

  • 9. A Case of Leukocytoclastic Vasculitis Following SARS-COV-2 Vaccination.
    Ball-Burack MR; Kosowsky JM
    J Emerg Med; 2022 Aug; 63(2):e62-e65. PubMed ID: 35690533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two Cousins with Acute Hemichorea after BBIBP-CorV (Sinopharm) COVID-19 Vaccine.
    Salari M; Etemadifar M
    Mov Disord; 2022 May; 37(5):1101-1103. PubMed ID: 35262222
    [No Abstract]   [Full Text] [Related]  

  • 11. New-onset leukocytoclastic vasculitis after COVID-19 vaccine.
    Bostan E; Gulseren D; Gokoz O
    Int J Dermatol; 2021 Oct; 60(10):1305-1306. PubMed ID: 34241833
    [No Abstract]   [Full Text] [Related]  

  • 12. [Leukocytoclastic vasculitis and acute renal failure following inactivated SARS-CoV-2 vaccine].
    Missoum S; Lahmar M; Khellaf G
    Nephrol Ther; 2022 Jul; 18(4):287-290. PubMed ID: 35074300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 vaccine-induced urticarial vasculitis.
    Dash S; Behera B; Sethy M; Mishra J; Garg S
    Dermatol Ther; 2021 Sep; 34(5):e15093. PubMed ID: 34369046
    [No Abstract]   [Full Text] [Related]  

  • 14. Leukocytoclastic vasculitis (cutaneous small-vessel vasculitis) after COVID-19 vaccination.
    Fiorillo G; Pancetti S; Cortese A; Toso F; Manara S; Costanzo A; Borroni RG
    J Autoimmun; 2022 Feb; 127():102783. PubMed ID: 34973526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous leukocytoclastic vasculitis after second dose of mRNA COVID-19 vaccine.
    Simon SC; Olsavszky V
    Dermatol Online J; 2022 Oct; 28(5):. PubMed ID: 36809133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 vaccination-induced cutaneous vasculitis: Report of two new cases and literature review.
    Abdelmaksoud A; Wollina U; Temiz SA; Hasan A
    Dermatol Ther; 2022 Jun; 35(6):e15458. PubMed ID: 35306713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Editorial: Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans.
    Galvan V; Quarleri J
    Geroscience; 2022 Feb; 44(1):57-61. PubMed ID: 34935099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous leukocytoclastic vasculitis following COVID-19 vaccination with Ad26.COV2.S vaccine: a case report and literature review.
    Đorđević Betetto L; Luzar B; Pipan Tkalec Ž; Ponorac S
    Acta Dermatovenerol Alp Pannonica Adriat; 2022 Jun; 31(2):83-87. PubMed ID: 35751559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous vasculitis due to COVID-19 vaccination.
    Gázquez Aguilera EM; Rodríguez García M; Cantón Yebra MT
    Med Clin (Barc); 2022 May; 158(10):493-494. PubMed ID: 34895746
    [No Abstract]   [Full Text] [Related]  

  • 20. Adverse events reported by Iranian patients with multiple sclerosis after the first dose of Sinopharm BBIBP-CorV.
    Ali Sahraian M; Ghadiri F; Azimi A; Naser Moghadasi A
    Vaccine; 2021 Oct; 39(43):6347-6350. PubMed ID: 34579974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.